Murine models of acute neuronopathic Gaucher disease
- 30 October 2007
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 104 (44), 17483-17488
- https://doi.org/10.1073/pnas.0708086104
Abstract
Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the glucosidase, beta, acid (GBA) gene that encodes the lysosomal enzyme glucosylceramidase (GCase). GCase deficiency leads to characteristic visceral pathology and, in some patients, lethal neurological manifestations. Here, we report the generation of mouse models with the severe neuronopathic form of GD. To circumvent the lethal skin phenotype observed in several of the previous GCase-deficient animals, we genetically engineered a mouse model with strong reduction in GCase activity in all tissues except the skin. These mice exhibit rapid motor dysfunction associated with severe neurodegeneration and apoptotic cell death within the brain, reminiscent of neuronopathic GD. In addition, we have created a second mouse model, in which GCase deficiency is restricted to neural and glial cell progenitors and progeny. These mice develop similar pathology as the first mouse model, but with a delayed onset and slower disease progression, which indicates that GCase deficiency within microglial cells that are of hematopoietic origin is not the primary determinant of the CNS pathology. These findings also demonstrate that normal microglial cells cannot rescue this neurodegenerative disease. These mouse models have significant implications for the development of therapy for patients with neuronopathic GD.Keywords
This publication has 42 references indexed in Scilit:
- Amyotrophic Lateral Sclerosis — Are Microglia Killing Motor Neurons?The New England Journal of Medicine, 2006
- Effective cell and gene therapy in a murine model of Gaucher diseaseProceedings of the National Academy of Sciences of the United States of America, 2006
- Onset and Progression in Inherited ALS Determined by Motor Neurons and MicrogliaScience, 2006
- Neuropathology provides clues to the pathophysiology of Gaucher diseaseMolecular Genetics and Metabolism, 2004
- Hematopoietic origin of microglial and perivascular cells in brainExperimental Neurology, 2004
- Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3Neurobiology of Disease, 2003
- MICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASESAnnual Review of Neuroscience, 1999
- Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease.JCI Insight, 1994
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseThe New England Journal of Medicine, 1991
- Rapidly Progressive Type III Gaucher Disease: Deterioration Following Partial SplenectomyActa Paediatrica, 1990